Markets:

Overview

News

Currencies

International

Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

42.96 -0.78 (-1.78%)

Streaming Delayed Price Updated: 9:47 AM EST, Jan 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

21 22 Next >

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Exelixis, Inc. - EXEL

August 09, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

August 05, 2025

From Pomerantz LLP

Via GlobeNewswire

Exelixis EXEL Q2 2025 Earnings Call Transcript ↗

August 04, 2025

Via The Motley Fool

Topics Earnings

Peering Into Exelixis's Recent Short Interest ↗

July 22, 2025

Via Benzinga

Peering Into Exelixis's Recent Short Interest ↗

July 04, 2025

Via Benzinga

Novo Nordisk, United Parcel Service, And Moderna Are Among Top 10 Large Cap Losers Last Week (July 28-August 1): Are The Others In Your Portfolio? ↗

August 03, 2025

Ten large-cap stocks, including Novo Nordisk and UPS, tumbled last week on weak earnings and guidance cuts.

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

August 01, 2025

From Pomerantz LLP

Via GlobeNewswire

EXELIXIS INC (NASDAQ:EXEL): A Strong Value Investment with Undervalued Potential and Solid Fundamentals ↗

July 30, 2025

EXELIXIS (EXEL) is a top value stock with strong fundamentals—undervalued P/E, zero debt, high profitability, and solid growth. Ideal for value investors seeking quality at a discount.

Via Chartmill

Assessing Exelixis: Insights From 20 Financial Analysts ↗

July 29, 2025

Via Benzinga

AMD Rises To 1-Year Highs, Crude Eyes $68: What's Moving Markets Tuesday? ↗

July 29, 2025

Risk appetite took a breather Tuesday, with major U.S. stock indices retreating modestly from record highs as investors braced for a pivotal stretch of earnings and macro events.

Via Benzinga

Analyst Surprised By Exelixis Q2 Revenue Miss, Delays STELLAR-304 Readout, Halts STELLAR-305 Phase 3 Plans ↗

July 29, 2025

Exelixis Q2 revenue missed estimates, but strong Cabometyx sales lifted earnings. STELLAR trial delays and strategy shifts shaped the update.

Via Benzinga

Whirlpool Posts Downbeat Earnings, Joins Harmonic, Stanley Black & Decker And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

July 29, 2025

Via Benzinga

Exelixis Q2 Revenue Falls 11 Percent ↗

July 28, 2025

Via The Motley Fool

Topics Earnings Intellectual Property

12 Health Care Stocks Moving In Monday's After-Market Session ↗

July 28, 2025

Via Benzinga

Curious about the stocks that are showing activity after the closing bell on Monday? ↗

July 28, 2025

After the closing bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.

Via Chartmill

Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update

July 28, 2025

From Exelixis, Inc.

Via Business Wire

EXELIXIS INC (NASDAQ:EXEL): A Prime Example of Affordable Growth in Biotech ↗

July 28, 2025

EXELIXIS (NASDAQ:EXEL) offers strong growth, fair valuation, and financial health, fitting the "Affordable Growth" strategy with high scores in profitability and low bankruptcy risk.

Via Chartmill

Topics Bankruptcy

Uncovering Potential: Exelixis's Earnings Preview ↗

July 25, 2025

Via Benzinga

Earnings Scheduled For July 28, 2025 ↗

July 28, 2025

Via Benzinga

EXELIXIS INC (NASDAQ:EXEL): A Strong Growth Stock with Bullish Technical Breakout Potential ↗

July 25, 2025

EXELIXIS INC (EXEL) combines strong growth fundamentals—high profitability, solid financials, and rising revenue—with bullish technical signals, making it a promising breakout candidate for investors.

Via Chartmill

Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

July 24, 2025

From Exelixis, Inc.

Via Business Wire

EXELIXIS INC (NASDAQ:EXEL) – A High-Growth Momentum Stock with Strong Technical Setup ↗

July 22, 2025

EXELIXIS INC (NASDAQ:EXEL) shows strong earnings momentum, expanding margins, and a high technical rating, making it a candidate for growth investors and breakout traders.

Via Chartmill

Here's Why This $50 Healthcare Stock Could Be the Next $200 Winner ↗

July 20, 2025

Via The Motley Fool

EXELIXIS INC (NASDAQ:EXEL) – A Strong Contender in High-Growth Oncology Stocks ↗

July 19, 2025

EXELIXIS (NASDAQ:EXEL) shows strong technical and fundamental growth, meeting Minervini’s Trend Template criteria with high earnings momentum and a bullish chart setup.

Via Chartmill

After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead. ↗

July 19, 2025

Yet another biopharma name has been run through a familiar trading cycle that often ends on a bullish note.

Via The Motley Fool

Topics Intellectual Property

Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025

July 14, 2025

From Exelixis, Inc.

Via Business Wire

Assessing Exelixis: Insights From 12 Financial Analysts ↗

July 10, 2025

Via Benzinga

EXELIXIS INC (NASDAQ:EXEL) – A Strong Contender for Growth Investors ↗

July 08, 2025

EXELIXIS INC (NASDAQ:EXEL) shows strong growth, profitability, and financial health, making it a standout for investors following Louis Navellier’s strategy. With high earnings surprises and...

Via Chartmill

EXELIXIS INC (NASDAQ:EXEL) – A Strong Growth Stock with Attractive Valuation ↗

July 05, 2025

EXELIXIS INC (NASDAQ:EXEL) offers strong growth potential at a reasonable valuation, backed by solid profitability and a debt-free balance sheet. A compelling pick for growth investors.

Via Chartmill

2 Stocks to Buy With Less Than $50 ↗

July 04, 2025

Via The Motley Fool

Topics Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.